Module home

Module introduction

Pre-module test

Module information

About the authors

Section 1: Background

(1.1) Section 1: Background

(1.2) Definitions

(1.3) Classification: generalised seizures

(1.4) Classification: partial seizures

(1.5) Prevalence of epilepsy in people with intellectual disability

(1.6) Factors influencing the prevalence

(1.7) Impact of epilepsy on people with intellectual disability

(1.8) Section 1: Recap

(1.9) Section 1: Summary

Section 2: Assessment and diagnosis

(2.1) Section 2: Assessment and diagnosis

(2.2) Types of intellectual disability

(2.3) Malformation of cerebral cortical development

(2.4) Epilepsy syndromes commonly associated with intellectual disability: West syndrome

(2.5) Epilepsy syndromes commonly associated with intellectual disability: Gastaut syndrome

(2.6) Epilepsy syndromes commonly associated with intellectual disability: Landau-Kleffner syndrome

(2.7) Diagnosis

(2.8) Investigations

(2.9) Section 2: Exercise

(2.10) Section 2: Exercise - answers to question 1

(2.11) Section 2: Exercise - answers to question 2

(2.12) Special issues to consider in people with intellectual disability

(2.13) Section 2: Recap

(2.14) Section 2: Summary

Section 3: Management and treatment

(3.1) Section 3: Management and treatment

(3.2) Management

(3.3) Treatment

(3.4) Special considerations

(3.5) Starting and combining anti-epileptic medication

(3.6) Barbiturates

(3.7) Carbamezapine (CBZ)

(3.8) Ethosuximide (ETM)

(3.9) Gabapentin (GBP)

(3.10) Lamotrigine (LTG)

(3.11) Levetiracetam (LEV)

(3.12) Oxcarbazepine (OXZ)

(3.13) Phenytoin (PHT)

(3.14) Pregabalin

(3.15) Sodium valproate (VPA)

(3.16) Tiagabine (TGB)

(3.17) Topiramate (TPM)

(3.18) Vigabatrin (VGB)

(3.19) Zonisamide

(3.20) Benzodiazepines

(3.21) NICE (2004) Guideline for anti-epileptic medication use

(3.22) Neurosurgery

(3.23) Other interventions

(3.24) Section 3: Recap

(3.25) Section 3: Summary

Module summary

Module test

Take-home notes

References

Send feedback